The widespread use of next generation sequencing for clinical testing is detecting an escalating number of variants in noncoding regions of the genome. The clinical significance of the majority of these variants is currently unknown, which presents a significant clinical challenge. We have screened over 6,000 early-onset and/or familial breast cancer (BC) cases collected by the ENIGMA consortium for sequence variants in the 5 ′ noncoding regions of BC susceptibility genes BRCA1 and BRCA2, and identified 141 rare variants with global minor allele frequency < 0.01, 76 of which have not been reported previously. Bioinformatic analysis identified a set of 21 variants most likely to impact transcriptional regulation, and luciferase reporter assays detected altered promoter activity for four of these variants. Electrophoretic mobility shift assays demonstrated that three of these altered the binding of proteins to the respective BRCA1 or BRCA2 promoter regions, including NFYA binding to . Clinical classification of variants affecting promoter activity, using existing prediction models, found no evidence to suggest that these variants confer a high risk of disease. Further studies are required to determine if such variation may be associated with a moderate or low risk of BC.
INTRODUCTION
Genetic susceptibility to breast cancer (BC) is complex. Multiple germline variants have been identified over the past 25 years that are broadly categorized as high, moderate, and low risk. High-risk variants are generally rare, have a major deleterious effect on gene function, are sufficient to confer a high risk of disease, and are highly penetrant within a family. Nonsense, splicing, large deletions, and some missense changes in BRCA1 and BRCA2 fall into this category (reviewed in Walsh et al., 2006) . There is also evidence that some alleles confer a moderate risk of cancer. These can include hypomorphic variants in known "high-risk" cancer syndrome genes Spurdle et al., 2012) , or clear loss-of-function alleles in other genes such as CHEK2, PALB2, and ATM (Couch et al., 2017) . Low-risk variants, largely identified by genome-wide association studies, are usually common and cause subtle functional effects, such as small but significant changes in gene expression due to altered activity of proximal and distal regulatory elements (reviewed in Bogdanova, Helbig, & Dork, 2013; Ghoussaini, Pharoah, & Easton, 2013; Skol, Sasaki, & Onel, 2016) .
Evidence suggests that combinations of low, moderate, and high-risk variants could confer a clinically significant risk of disease (Ding et al., 2012; Kuchenbaecker et al., 2017; Sawyer et al., 2012) . Identification and evaluation of all such variants is therefore crucial for accurately predicting BC risk.
Use of next generation sequence analysis for germline clinical testing of cancer cases is identifying an increasing number of variants in noncoding regions of cancer susceptibility genes, including promoters, untranslated regions (UTRs), and introns. There are currently no firm recommendations for assessing the relevance of noncoding region variants to clinical testing of Mendelian disease genes, and so the vast majority of such variants are deemed of uncertain clinical significance.
This adds to the clinical challenge presented by variants of uncertain significance, namely that they complicate test reporting and genetic counseling, limit patient eligibility for intensive surveillance and genetargeted therapies, and prevent gene testing and guided management of relatives (reviewed in Amendola et al., 2015; Eccles et al., 2013; Plon et al., 2011) . It is therefore essential that the functional and clinical significance of variants mapping to noncoding regions of the genome is determined.
Gene expression is controlled at many levels with key regulatory elements being housed in noncoding regions of the genome, such as gene promoters, introns, long-range elements, and 5 ′ and 3 ′ UTRs.
The BRCA1 gene is regulated at the transcriptional and posttranscriptional levels, with functional proximal and distal regulatory elements being described in the promoter, introns, and UTRs, by us and others (Brewster et al., 2012; Brown et al., 2002; Santana dos Santos et al., 2017; Saunus et al., 2008; Tan-Wong, French, Proudfoot, & Brown, 2008; Wardrop, Brown, & kConFab, 2005; Wiedemeyer, Beach, & Karlan, 2014) . Although less studied, the BRCA2 promoter has also been mapped and characterized (reviewed in Wiedemeyer et al., 2014) .
Common and rare variations in regulatory elements upstream of genes have been shown to alter gene expression and be associated with disease risk (reviewed in Betts, French, Brown, & Edwards, 2013; Diederichs et al., 2016; Millot et al., 2012) . We and others have described germline cancer-associated variants in the regulatory regions, including large deletions in the BRCA1 promoter (Brown et al., 2002) , and single nucleotide variants in the promoter and/or 5 ′ UTR of BRCA1 and BRCA2 (Evans et al., 2018; Santana dos Santos et al., 2017) , MLH1 promoter (Hitchins et al., 2011) , POLG promoter (Popanda et al., 2013) , PTEN promoter (Heikkinen et al., 2011) , TERT promoter (Horn et al., 2013) , KLHDC7A and PIDD1 promoters (Michailidou et al., 2017) , BRCA1 3 ′ UTR (Brewster et al., 2012) , and BC-associated Single Nucleotide Polymorphisms (SNPs) in long-range enhancers of CCND1 .
Cancer risk-associated variants within regulatory regions are anticipated to mediate an effect on trans-acting regulatory factors (e.g., transcription factors [TFs] and miRNAs), by disrupting binding of regulatory factors and interactions between regulatory elements, such as promoter-enhancer interactions. For example, a variant in a Cyclin D1 transcriptional enhancer has been associated with altered binding of the ELK4 TF and a variant within the BRCA1 3 ′ UTR has been shown to introduce a functional mir-103 binding site (Brewster et al., 2012) . In addition, a dominantly inherited 5 ′ UTR BRCA1 variant was recently shown to be associated with BRCA1 promoter hypermethylation, which is known to impact TF binding, and associated allelic loss of BRCA1 expression in two families affected by breast and ovarian cancers (Evans et al., 2018) .
In this paper, we describe 141 germline variants in the BRCA1 and BRCA2 promoter, identified by members of the ENIGMA consortium in early onset or familial BC patients with no known pathogenic variants in the coding region of these genes. Using a combination of bioinformatic and experimental analyses, we have prioritized and analyzed a subset of variants that are most likely to affect the regulation of BRCA1 and BRCA2 and thus have the most potential to contribute to BC risk.
TF binding site affinity changes resulting from these variants were subsequently analyzed by information theory (IT)-based analyses. In parallel, we have assessed if these variants exhibited the features expected for a high-risk pathogenic BRCA1 or BRCA2 variant, on the basis of available clinical and population data.
MATERIALS AND METHODS

Study design
An overview of the study design is shown in Figure 1 . Collection of variants at all sites enabled an initial catalogue of variants from which variants were prioritized for functional analysis. Additional screening was carried out at three sites, Maastricht (M), Santiago (S), and Prague (Pr), that included additional patients (M, S, and Pr) and controls (Pr) that expanded the list of variants (Pr), the number of patients (M, S, and Pr), and included control subjects (Pr).
Clinical and control samples
Clinical and genetic data were collected and analyzed in accordance with local human ethics guidelines of the institutions contributing to this study. All participating individuals provided informed consent for their data to be used for research purposes. An overview of the samples analyzed is shown in (Lhota et al., 2016; Soukupova, Zemankova, Kleiblova, Janatova, & Kleibl, 2016) ; and 130 healthy females without cancer diagnosis recruited in Santiago de Compostela.
Identification of variants
Regions containing the BRCA1 and BRCA2 promoter and 5 ′ UTR were sequenced using a range of standard DNA sequencing technologies, and bioinformatic filtering pipelines. Variants mapping to the 2,400 bp region (hg19; chr17:41,278,514 -41,276,114) of BRCA1 and the 2,000 bp region (hg19; chr13: 32,888,597-32,890,597) of BRCA2 were considered for further analysis. The identified variants in BRCA1 and BRCA2 5 ′ noncoding regions are numbered whereby the first translated nucleotide of the translation initiation codon is +1 (https://varnomen.hgvs.org/) using the Mutalyzer website (https://mutalyzer.nl/). BRCA1 is described using NC_000017.10 (hg19 genomic sequence) and NM_007294.3 (transcript). BRCA2 is described using NC_000013.10 (hg19 genomic sequence) and NM_000059.3 (transcript). 
TA B L E 1 Samples used in this study
In silico TF binding analysis
All rare variants were analyzed in silico using an IT-based method Mucaki et al., 2016) and a modified version of the Shannon pipeline utilizing TF information models built from ENCODE ChIP-seq datasets (Lu, Mucaki, & Rogan, 2017) to assess potential effects of variants on TF binding. Details of analyses are contained in Supporting Information Methods. The luciferase-based reporter assay was performed as described previously (Brewster et al., 2012) . Positive controls were B1-Ets, BRCA1:c.-330_-329delinsTT, that decreases BRCA1 promoter activity in MCF7 cells (Atlas, Stramwasser, Whiskin, & Mueller, 2000) and B2-Ets (E2Fmut1: BRCA2:c.-282_-281delinsAA), that has been shown to decrease BRCA2 promoter activity in MCF7 cells (Davis, Miron, Andersen, Iglehart, & Marks, 1999) . Statistical analyses were performed in GraphPad Prism using one-way analysis of variance followed by Tukey's post hoc test and values P < 0.05 were deemed statistically significant.
Experimental analysis of variants 2.5.1 Promoter reporter assays
Electrophoretic mobility shift assays
Nuclear proteins were extracted as described in Supporting Information Methods and electrophoretic mobility shift assays (EMSAs)
were carried out using a Pierce LightShift Chemiluminescent EMSA Kit (Thermo Fisher, Waltham, MA) with modifications described in Supporting Information Methods. For competition and supershift studies, nuclear extracts were initially incubated with unlabeled double-stranded (ds) competitor probes or antibodies in binding buffer before addition of the biotinylated probe and incubation at room temperature. Positive controls for BRCA1 and BRCA2 DNA binding were sequences surrounding the B1-Ets and B2-Ets mutations described above.
Qualitative and quantitative classification of variants
Variants were classified according to the ENIGMA classification criteria for variation in BRCA1 and BRCA2 (https://enigmaconsortium.org/)
to determine whether any of the prioritized variants were associated with a high risk of disease. See Supporting Information Methods for further details.
RESULTS
Identification and prioritization of sequence variants in BRCA1 and BRCA2 5´noncoding regions
The 5 BRCA2 variants resided within the minimal promoter regions.
To predict the potential impact of variants on promoter activity, we prioritized variants using breast cell specific data for chromatin accessibility and TF occupancy along with evolutionary conservation. Due to the limited breast cell specific TF ChIP-seq data, we also included ENCODE TF ChIP-seq and TF consensus motif data from all cell lines.
A total of nine BRCA1 and 12 BRCA2 variants were selected for further functional analysis (Figure 2 ; Tables 2 and 3 ).
BRCA1 and BRCA2 promoter activity is altered by 5 ′ noncoding sequence variants
To examine the potential effect of the 21 prioritized BRCA1 and BRCA2 
In silico analyses of BRCA1 and BRCA2 5 ′ variants predict alterations in TF binding
BRCA1 and BRCA2 promoters are regulated by a complex array of DNA-binding proteins and transcriptional coactivators and corepressors (reviewed in McCoy, Wiedemeyer et al., 2014) . In silico analysis was carried out to examine whether the BRCA1 and BRCA2 promoter variants shown to alter luciferase activity (see above) are likely to affect binding of trans-acting protein factors in breast cells.
Interrogation of ENCODE ChIP-seq datasets derived from breast cell lines show that, although the number of datasets is limited, TFs bind to regions encompassing the prioritized variants ( Figure 2 and Supporting Information Figure S1 ). ENCODE ChIP-seq data from other cell lines indicate that some variants are located within consensus motifs for specific TFs associated with these regions (Tables 2   and 3 ; Supporting Information Figure S1 ). 
5 ′ variants in BRCA1 and BRCA2 alter protein-DNA interactions in EMSA analyses
To examine potential alterations in the binding of nuclear proteins from breast cells by the BRCA1 and BRCA2 promoter variants that altered luciferase activity, we carried out EMSA analysis. For Figure 6a) .
Competition experiments showed that these interactions were specific and not competed by a nonspecific probe from an unrelated region of the BRCA1 promoter (Figure 6a ).
To determine the effect of these variants on the binding of specific Figure S1a ), and IT analysis predicts that the variant disrupts binding of these TFs (Table 4 ). Consistent with these predictions, supershift experiments show that BRCA1:c.-287C>T disrupts binding of NFYA to this region ( Figure. 5d ). In addition, we analyzed BRCA2:c.-296C>T, which maps within the consensus binding motif for PAX5 (Table 2 and Supporting Information Figure S1b ), and is predicted by IT analysis to disrupt binding of PAX5 (Table 4) Table S3 ). Review of variant frequency in public reference groups identified 21 variants that were classifiable, as Not Pathogenic, based on frequency in control groups (Supporting Information Table S5 ): six BRCA1 and five BRCA2 variants were observed at >1% frequency in population subgroups (stand-alone evidence against pathogenicity, when detected in a nonfounder outbred population group); six BRCA1 and four BRCA2 variants occurred at frequency 0.001-0.01 (range 0.0014-0.0076) in at least five individuals in the reference set, which combined with a low assumed prior is considered sufficient as evidence against pathogenicity (Supporting Information Table S5 ). Frequency data from controls screened for this study also supported the frequency-based classifications for eight of these 21 variants (Supporting Information Table S5 ).
Clinical classification of BRCA1 and BRCA2 5 ′ noncoding sequence variants
Segregation analysis for seven informative families aided classification for six variants, whereas histopathology likelihood ratios (LRs) derived for 24 tumors altered classification for 10 variants (Supporting Information Likely Not Pathogenic based on frequency information and/or multifactorial analysis (Table 5) disease. This analysis is silent, however, on whether these variants may confer a moderate or low risk of disease.
DISCUSSION
Next generation sequencing and gene panel testing enable rapid analysis of gene regions that have previously not been included in standard screening procedures, including promoters, UTRs, introns, and extragenic regions. It is hypothesized that variants in these regions have potential to modulate gene expression (Stranger et al., 2005; Stranger et al., 2007) and impact on relative disease risk, possibly in collaboration with multiple other low-, moderate-, and high-risk variants (Manolio et al., 2009 The observed alterations in BRCA1 and BRCA2 promoter activity are of a similar magnitude to that seen with other germline variants associated with BC risk (Michailidou et al., 2017) , including a variant in the TERT promoter, which creates a new binding site for Ets factors and results in a 1.2-1.5-fold increase in luciferase activity in a promoter reporter assay (Horn et al., 2013) , and variants in the promoters of KLHDC7A and PIDD1 (Michailidou et al., 2017) . Although this supports the hypothesis that moderate change in promoter activity can be associated with disease risk, further work is needed to confirm this.
One of the four variants significantly altered luciferase activity in both tested cell lines, whereas the remaining three variants only affected luciferase activity in MCF7 cells. This may reflect the differential availability of crucial TFs in MDA-MB-468 cells (Kao et al., 2009) and highlights the importance of undertaking that assays for functional activity of variants in more than one cell line. Three variants, BRCA1:c.- Overall, however, the consistency of results performed in two separate laboratories underscores the robustness of the assay system. Some variants were associated with a decrease in promoter activity, whereas others were associated with an increase. As TFs can Posterior probabilities used to assign IARC 5-tier class as described in Plon et al., 2008 . Figure S1 ). These include E2F1, CEBPB, GATA3, Max, ELF1, GABP, and FOXA1 for BRCA1 and E2F1, MYC, ELF1, GABP, Max, and PML for BRCA2. Interestingly, a number of these factors have previously been implicated in BC.
In addition, ENCODE ChIP-seq data from cell lines derived from tissues other than breast indicate that the variants that affect protein binding are located within consensus motifs for specific TFs associated with these regions (Tables 2 and 3 ; Supporting Information Figure S1 ). (Gochhait et al., 2007) .
Using existing prediction models developed for high risk variants, population frequency and clinical information classified 27 variants as "Not Pathogenic" or "likely Not Pathogenic. " This included two BRCA1 and six BRCA2 variants with functional assay data available, six with no statistically significant effect on promoter activity, and two that decreased promoter activity in vitro. These two variants, variation. This suggests that promoter region variants, irrespective of bioinformatic prediction or functional assay results, are unlikely to be associated with a high risk of cancer. This is consistent with current evidence from ENIGMA studies (de la Hoya et al., 2016) , which suggest that an allele resulting in only ∼20-30% expression of BRCA1 transcript/s encoding functional transcripts is not associated with high risk of BC. The low impact of these variants on risk is likely to reflect the complex interplay of TFs and DNA elements, and possible redundancy in the system. For example, a variant in one TF binding site within a cluster may be buffered by other binding sites and thus insufficient on its own to reduce gene expression markedly (Lu & Rogan, 2018) .
Given that moderate-and low-risk variants often occur in >1% of the population, and that the remaining 13 variants had insufficient evidence available to assess clinical significance, we cannot exclude the possibility that BRCA1/2 promoter region variants, in particular those with proven functional effect, may be associated with a moderate or low risk of cancer. This indicates an urgent need to further develop prediction models to accommodate criteria for moderate-or lowrisk variants by extending the BRCA1/2-specific criteria developed by ENIGMA (https://www.enigmaconsortium.org/), or even the generic variant classification criteria developed by the American College of Medical Genetics for Mendelian disorders (Richards et al., 2015) .
This study has evaluated the significance of single nucleotide variants and small indels mapping to the 5 ′ noncoding region of BRCA1 and BRCA2 using bioinformatic, biological, and biochemical analyses in combination with consideration of clinical data that inform qualitative and quantitative variant classification. We present data to suggest that a subset of these variants have functional effects on gene regulation.
We also present evidence that variants mapping to and affecting the function of BRCA promoters are not likely to be associated with a high risk of cancer. We propose that studies of differing design, such as very large-scale case-control sequencing studies able to detect rare variation, will be required to address if a low to moderate risk of cancer may be associated with BRCA1/2 regulatory region variation that has not been captured to date by genome-wide association genotyping platforms. We believe that the bioinformatic and functional analysis presented will be important to define the design and interpretation of such future sequencing studies. We also believe that this study highlights the challenges associated with classifying variants with respect to low or moderate disease risk, and the need to be cautious in the clinical use of information on individual variants that is likely to be one of many factors contributing to disease risk.
